BMPR-1A Overview
Molecule Name
Bone morphogenetic protein receptor type-1A
Synonyms
BMPR-1A,ALK-3,ACVRLK3,CD292,SKR5
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs2
Highest Development StageApproved
Target Synonym
Bone Morphogenetic Protein Receptor Type 1A，EC 2.7.11，Activin receptor-like kinase 3，Bone morphogenetic protein receptor type-1A，ALK3，BMPR1A，Bone Morphogenetic Protein Receptor， Type IA，Serine/Threonine-Protein Kinase Receptor R5，ACVRLK3，BMPR-1A，SKR5，Activin A Receptor， Type II-Like Kinase 3，CD292 Antigen，EC 2.7.11.30，10q23del，CD292，BMP type-1A receptor，ALK-3，EC:2.7.11.30
Background
The bone morphogenetic protein receptor, type IA is also known as BMPR1A or ALK3 is a protein which in humans is encoded by the BMPR1A gene. BMPR1A has also been designated as CD292 (cluster of differentiation 290). The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A (this protein) and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. Alk3-mediated BMP signaling in AV endocardial/mesenchymal cells plays a central role during cushion morphogenesis.
BMPR-1A Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant Human Bone Morphogenetic Protein-2（University Of Baghdad） | Phase 1 Clinical | University Of Baghdad | Diabetes Mellitus; Hematologic Diseases; Hypertension | Details | |
| Recombinant human bone morphogenetic protein 4 (Stemgen) | HS-214; hrBMP4 | Phase 1 Clinical | Stemgen | Asthma; Bronchiolitis Obliterans; Glioblastoma; Lung Diseases; Rejection of lung transplantation | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dibotermin alfa | YM-484; rhBMP-2/CPM | Approved | Medtronic | Inductos | EU | Tibial Fractures | Medtronic Biopharma Bv | 2002-09-09 | Fractures, Bone; Osteoarthritis; Osteoarthritis, Spine; Radius Fractures; Tibial Fractures; Tooth Injuries | Details |
| DWP-431 | DWP-431; rhBMP-2 | Approved | Daewoong Pharmaceutical Co Ltd | Novosis, Novosis-Dental | South Korea | Alveolar Bone Loss | Daewoong Pharmaceutical Co Ltd | 2013-01-01 | Alveolar Bone Loss; Intervertebral Disc Degeneration | Details |